- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05715684
Préhabilitation chirurgicale centrée sur le patient (Prehab)
The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This research study is testing the efficacy of the prehabilitation study which is a set of investigational interventions and also tries to define the most appropriate and effective set type of interventions to use for further studies. "Investigational" means that the intervention is being studied. In this research study, the investigators hope to learn whether or not this combination of prehabilitation interventions has an impact on the recoverability of participants who will undergo cystectomy or bladder removal surgery. The 5 interventions that make up the prehabilitation study are:
- Participant Interview (If one of the first ten participants)
- Exercise Testing
- Exercise Training
- Nutritional Support
- Clinical Assessment of Nutritional Status
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Matthew Mossanen, MD, MPH
- Numéro de téléphone: 617-732-6384
- E-mail: mmossanen@bwh.harvard.edu
Sauvegarde des contacts de l'étude
- Nom: Nnamdi Onochie
- Numéro de téléphone: 6175258753
- E-mail: nnamdi_onochie@dfci.harvard.edu
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Brigham and Women's Hospital
-
Chercheur principal:
- Matthew Mossanen, MD
-
Contact:
- Matthew Mossanen, MD
- Numéro de téléphone: (617) 732-6384
- E-mail: mmossanen@bwh.harvard.edu
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Dana Farber Cancer Institute
-
Contact:
- Matthew Mossanen, MD
- Numéro de téléphone: 617-732-6384
- E-mail: mmossanen@bwh.harvard.edu
-
Chercheur principal:
- Matthew Mossanen, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patents must be candidates for all types of cystectomy surgery including urinary diversion via open or robotic approach.
- Patients between the ages 18 and 85 years
- American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4
- Ileal conduit or ileal neobladder urinary diversion
- Able to understand the study procedures, agreed to participate in the study program, and voluntarily provided informed consent
Exclusion Criteria:
- Scheduled for a partial cystectomy
- Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy
- More than three doses of opioids (oral or parenteral) within 7 days before the day of surgery
- The presence of metastatic cancer
- Be undergoing treatment for another type of cancer concurrently
- Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed.
- Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam; or abstinence) (Participants will be asked to use birth control for the entire study and for at least 2 weeks after the last dose of study drug.)
- Participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study
- Clinically significant laboratory abnormalities at screening that would have resulted in the cancellation of surgery
- Using illicit drugs or abusing alcohol
- History of previous surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might have confounded the study results or might have posed additional risk in administering the study procedures
- Patients with severe dementia (as determined from medical records and history. Severe dementia will be defined as dementia that impacts daily functioning.)
- Patients with severe hepatic impairment as defined by Child-Pugh Class C. Patients with Child-Pugh Class A-B hepatic impairment are eligible for the study.
- A history of heart failure.
- Patients with end-stage renal disease as defined by GFR <15.
- Patients with heart failure.
- Patients with complete gastrointestinal obstruction.
- Patients with gastrostomy tube, jejunostomy tube or who require enteral tube feeds.
- Non-English-speaking patients
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Standard treatment Plan
This is the main arm of the study in which all 25 anticipated participants will be enrolled into. |
Virtually supervised exercise training for four weeks prior to cystectomy Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total days hospitalized within 30-days of surgery
Délai: 60 months
|
This is the total number of days within 30 days after bladder removal surgery, that a patient is hospitalized. |
60 months
|
|
Length of stay
Délai: 60 months
|
This is the total length of stay in days after bladder removal surgery |
60 months
|
|
Number and type of minor and major complications
Délai: 60 months
|
This is the number and types of major and minor complications which occur post bladder removal surgery |
60 months
|
|
Discharge disposition
Délai: 60 months
|
This is the disposition of the patient at discharge or when the patient is released from the hospital. |
60 months
|
|
Readmissions
Délai: 60 months
|
This is the number of times a patient that was discharged come back to the hospital for any issue related to their bladder removal surgery. |
60 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Tumeurs urologiques
- Maladies de la vessie urinaire
- Tumeurs de la vessie urinaire
- Activité motrice
- Mouvement
- Phénomènes physiologiques musculo-squelettiques
- Phénomènes physiologiques musculo-squelettiques et neuronaux
- Exercice
Autres numéros d'identification d'étude
- 22-329
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Délai de partage IPD
Data can be shared no earlier than 1 year following the date of publication
Critères d'accès au partage IPD
Contact the Partners Innovations team at http://www.partners.org/innovation
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .